This inventor holds 6 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: The University of North Carolina at Chapel Hill, Genecentric Therapeutics, Inc., Regents of the University of Minnesota. Active years: 2021-2026.
Location History:
- Duham, NC (US) (2021)
- Chapel Hill, NC (US) (2022)
Company Filing History:
6 out of 1,325 
4 out of 10 
1 out of 2,367 
Years Active: 2021-2026
Title: The Innovative Contributions of Jonathan Serody
Introduction
Jonathan Serody is a prominent inventor based in Durham, NC (US), known for his significant contributions to the field of cancer research. With a total of 6 patents, he has made strides in understanding and treating lung adenocarcinoma and lung squamous cell carcinoma. His work focuses on developing methods and compositions that enhance the precision of cancer therapies.
Latest Patents
Among his latest patents, Serody has developed methods for subtyping lung adenocarcinoma. These methods involve determining a subtype of lung adenocarcinoma (AD) by detecting the expression level of classifier biomarkers from a group of gene signatures. Additionally, he has created methods for assessing the response of individuals with adenocarcinoma subtypes to therapies such as immunotherapy. Furthermore, he has patented methods for subtyping lung squamous cell carcinoma (SQ) using similar techniques, which also include evaluating responses to immunotherapy.
Career Highlights
Throughout his career, Jonathan Serody has worked with esteemed institutions, including the University of North Carolina at Chapel Hill and Genecentric Therapeutics, Inc. His research has been pivotal in advancing the understanding of cancer subtypes and their treatment options.
Collaborations
Some of his notable coworkers include Hawazin Faruki and Myla Lai-Goldman, who have collaborated with him on various research projects.
Conclusion
Jonathan Serody's innovative work in cancer research has led to significant advancements in the understanding and treatment of lung cancers. His contributions continue to impact the field and improve patient outcomes.